IŞIL BULUR, Ebru ÖZEN, Serdar EKEMEN, Yunus TÜRKMEN, Birgül Büyükkıdan YELKEN

NONİYONİK KONTRAST MADDE (İOHEKSOL) İLE İLİŞKİLİ NADİR BİR KOMPLİKASYON: TOKSİK EPİDERMAL NEKROLİZİS

Toksik Epidermal Nekrolizis (TEN) nadir görülen ve hayatı tehdit eden mukokutanöz bir hastalıktır. Artmış kerotinosit hücreölümü sonucu dermal-epidermal bileşkede geniş cilt alanlarında ayrışma ve haşlanmış deri görünümü ile karakterizedir. Sıklıklailaç alımı ile ilişkili olup noniyonik iyodinize kontrast madde uygulamasını takip eden TEN çok nadirdir. Bu yazımızda monomeriknoniyonik iyotlu kontrast madde olan ioheksol'e bağlı gelişen bir TEN olgusunu sunmayı amaçladık

A RARE COMPLICATION ASSOCIATED WITH NONIONIC CONTRAST MEDIA (IOHEXOL): TOXIC EPIDERMAL NECROLYSIS

Toxic Epidermal Necrolysis (TEN) is a rare and life threatening mucocutaneous disease. It is characterized by the separationof significant areas of skin at the dermal–epidermal junction due to extensive keratinocyte cell death and the appearance of scaldedskin. It is frequently related to drug intake. Toxic Epidermal Necrolysis following administration of nonionic iodinated contrastmedia is very rare. In this paper, we report a case of TEN induced by nonionic iodinated contrast medium iohexol

PDF

___

1. French LE, Prins C. Erythema multiforme, Steven-Johnson syndrome and toxic epidermal necrolysis. In Bolognia, Dermatology, Elsevier, 2nd edn. 2012: 319-333.
2. Savill JS, Barrie R, Ghosh S, Muhlemann M, Dawson P, Pusey CD. Fatal Stevens-Johnson syndrome following urography with iopamidol in systemic lupus erythematosus. Postgrad Med J 1988; 64: 392-394.
3. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/ toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1: 349-360.
4. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137: 765-770.
5. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43-47.
6. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune disease. J Am Acad Dermatol 2001; 44: 1010-1024.
7. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med 1996; 2: 317-322.
8. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-493.
9. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with stevens-johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature. Pediatrics 2003; 112: 1430-1436.
10. Alpsoy E, Dicle Ö, Karakafl AA. Steven-Johnson Sendromu ve Toksik Epidermal Nekroliz. Turkderm 2010; 44: 180-186.
11. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-327.
12. Rappersberger K, Foedinger D. Treatment of erythema multiforme, Stevens-Johnson Syndrome, and toxic epidermal necrolysis. Dermatologic Therapy 2002; 15: 397-408.
13. Lam NS, Yang YH, Wang LC, Lin YT, Chiang BL. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children. J Microbiol Immunol Infect 2004; 37: 366-370.
14. Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol 2007; 87: 144-148.
15. Prins C, Kerdel AF, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
16. Mittmann N, Chan B, Knowles S, Cosentino L, Shear N. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006; 7: 359-368.